NF-κB signaling in diabetic cardiomyopathy:mechanisms and therapeu-tic advances
10.3969/j.issn.1000-4718.2025.09.022
- VernacularTitle:NF-κB信号通路在糖尿病心肌病中作用及靶向治疗的研究进展
- Author:
Letian YU
1
;
Shunlin QU
1
Author Information
1. 南华大学心血管疾病研究所,湖南省动脉硬化学重点实验室,湖南省动脉硬化性疾病国际联合科技创新合作基地,湖南 衡阳 421001
- Publication Type:Journal Article
- Keywords:
diabetic cardiomyopathy;
nuclear factor-κB;
inflammation;
targeted therapy;
ventricular dysfunction
- From:
Chinese Journal of Pathophysiology
2025;41(9):1855-1861
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic cardiomyopathy(DCM)is a prevalent cardiovascular complication associated with diabe-tes,which is characterized by abnormalities in heart structure and function.Chronic inflammation,which is mediated by the nuclear factor-κB(NF-κB)signaling pathway,is pivotal in the onset and progression of DCM.NF-κB can be activated by diabetes-related factors,including hyperglycemia,oxidative stress,and endoplasmic reticulum stress,which in turn promote the expression of inflammatory cytokines,chemokines,and adhesion molecules.This cascade leads to cardiac in-flammation,fibrosis,and apoptosis.Therefore,we summarized the role of the NF-κB signaling pathway in DCM,particu-larly its activation mechanisms and downstream reactions.The regulatory effects of cytokines,receptors,reactive oxygen species,and other factors involved in NF-κB activation were also analyzed.In addition,potential therapeutic strategies to modulate NF-κB activity,including natural compounds,synthetic inhibitors,gene therapy,and monoclonal antibodies,were summarized in this study.Targeting the NF-κB signaling pathway can mitigate the inflammatory response and en-hance cardiac function in patients with DCM.However,the development of selective and effective NF-κB inhibitors,along with the validation of their safety and efficacy through clinical trials,remains a critical focus for future research.
